In 2006, Loveland et al. published a phase 1 clinical trial that utilized autologous dendritic cells treated with mannin-MUC1 fusion protein in ten patients with adenocarcinomas that were either stage IV or had progressed during prior therapy. The gene discussed is MUC1; the disease is adenocarcinoma.